Roche, Recursion advance first AI-discovered drug target

Roche ↘ 1.99% and its subsidiary Genentech have advanced the first neuroscience drug target to emerge from their artificial intelligence partnership with Recursion Pharmaceuticals ↘ 8.64%, moving it into an early discovery program in what both companies describe as a proof point for AI-driven drug development in one of medicine's most difficult fields.

A First From a Sprawling Partnership

The milestone, announced alongside Recursion's second-quarter earnings on August 5, represents the first concrete output from a collaboration that began in December 2021 and could encompass up to 40 individual programs worth more than $300 million each in potential milestone payments. The target, aimed at an undisclosed neurodegenerative disease, was identified through AI analysis of Recursion's proprietary datasets and then validated through laboratory experiments by both partners.fiercebiotech+1

"The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point," Recursion CEO Najat Khan said. "Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled."linkedin

Why Neuroscience Needs New Approaches

The collaboration draws on Recursion's "Microglia Map," a whole-genome phenotypic database built from approximately 46 million images that links over 17,000 genes to their observable effects on microglia, the brain's primary immune cells. The map, announced last October, gives researchers a way to systematically explore how genes and compounds may be implicated in neurological diseases — an area where drug development failure rates remain among the highest in medicine.recursion

According to Bloomberg, the target emerged from a joint effort combining Recursion's image-based AI platform with single-cell profiling data from Roche and Genentech.roche+1

What Comes Next

Genentech has now optioned this first target into an early discovery program, though neither company disclosed which neurodegenerative condition it addresses. The partnership, which Roche initiated with a $150 million upfront payment, is designed to run for up to a decade across neuroscience and oncology. Recursion outlined $375 million in 2026 cash operating expense guidance as part of its quarterly results.recursion+3